



Attorney's Docket No.: 10274-008003

GAU 1642  
Box SEQ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Linda C. Burkly

Art Unit : 1642

Serial No. : 09/234,290

Examiner : S. Ungar

Filed : January 20, 1999

Title : TREATMENT FOR INSULIN DEPENDENT DIABETES

Box Sequence Listing  
Assistant Commissioner for Patents  
Washington, D.C. 20231

RECEIVED

MAR 24 2000

TECH CENTER 1600/2800

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS  
FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE AND/OR AMINO ACID SEQUENCES

In response to the communication dated January 18, 2000, Applicant submits herewith a Sequence Listing in computer readable form as required by 37 CFR §1.824. In addition, Applicant submits a Sequence Listing as required under 37 CFR §1.823(a) and a statement under 37 CFR §1.821(f). 3-23-00

Applicant notes that newly added SEQ ID NO: 16 is a translation of original SEQ ID NO: 9.

I hereby state that this submission, filed in accordance with 37 CFR §1.821(g), does not contain new matter.

A petition for one-month extension of time is being filed on even date herewith with an Amendment and Response to Species Election.

Please charge any necessary fee to our Deposit Account No. 06-1050.

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

March 20, 2000

Date of Deposit

Sandra Sturtevant

Signature

Sandra Sturtevant

Typed or Printed Name of Person Signing Certificate

Applicant :  
Serial No. : 09/234,290  
Filed : January 20, 1999  
Page : 2



Attorney's Docket No.: 10274-008003

RECEIVED

Respectfully submitted,

MAR 24 2000

Date: 20 Mar 00

TECH CENTER 1600/2900

P. Louis Myers  
Reg. No. 35,965

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804  
Telephone: (617) 542-5070  
Facsimile: (617) 542-8906

20040127.doc



PATENT  
ATTORNEY DOCKET NO. 10274/008003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Linda C. Burkly

Art Unit: 1642

Serial No.: 09/234,290

Examiner: S. Ungar

Filed : January 20, 1999

Title : TREATMENT FOR INSULIN DEPENDENT DIABETES

Box Sequence

Assistant Commissioner for Patents  
Washington, DC 20231

VERIFIED STATEMENT UNDER 37 CFR § 1.821 (f)

I, Maureen Ruttle, declare that I personally prepared the paper and the computer-readable copies of the Sequence Listing filed herewith in the above-entitled case and that the content of both is the same.

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of The United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Date: March 20, 2000

Maureen Ruttle  
Maureen Ruttle

Fish & Richardson P.C.  
225 Franklin Street  
Boston, MA 02110-2804

Telephone: 617/542-5070  
Facsimile: 617/542-8906

Date of Deposit March 20, 2000  
I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Sandra Sturtevant  
Sandra Sturtevant

MAR 23 2000

Application No.

09/234,290

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 CFR 1.821 - 1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.

2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CFR 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).

7.

Other: \_\_\_\_\_

**Applicant must provide:**

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d)

For questions regarding compliance with these requirements, please contact:

For Rules Interpretation, call (703) 308-1123  
For CRF submission help, call (703) 308-4212  
For PatentIn software help, call (703) 557-0400

Please return a copy of this notice with your response.